PuraPharm Corporation Limited (1498.HK) Stock

About PuraPharm Corporation Limited

PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. It operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. The company offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. It also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provides Chinese medicine services and CCMG products. In addition, the company engages in the plantation and trading of raw Chinese herbs; manufacture and sale of traditional Chinese medicine decoction pieces; provision of modernized Chinese medicine services, Chinese medical diagnostic services; and research and development of new products and bio-based polymeric materials. Further, It operates an online platform. PuraPharm Corporation Limited was incorporated in 1998 and is headquartered in Tai Po, Hong Kong.

PuraPharm Corporation Limited is led by CEO Yu Ling Chan, employs 441 people, headquartered in Hong Kong, HK, publicly traded since 2015.

PuraPharm Corporation Limited (1498.HK) stock trades at $0.28 with a market capitalization of $149.81M. The stock is valued at a price-to-earnings (P/E) ratio of -3.50, price-to-book of 1.15, price-to-sales of 0.45. Over the past 52 weeks the stock has ranged between $0.27 and $0.49, and currently trades 42.9% below its 52-week high.

On profitability, PuraPharm Corporation Limited generates a return on equity (ROE) of -29.15%, an operating margin of -0.19%, a net profit margin of -10.48%.

Official website: www.purapharm.com